In recent years, there has been a growing convergence between the worlds of health technology and biopharma. Decentralized clinical trials are a prime example of this trend. But even before the pandemic that led to the rapid scale of decentralized trials, biopharmaceutical companies were experimenting with various technologies in R&D.

Using machine learning and other forms of AI for drug development is an exciting trend full of possibilities, especially as technology matures and companies adapt.

AI in drug development is just one of the roundtables at the virtual MedCity INVEST PhrmaTech conference, scheduled for Tuesday, July 26.

To see the full agenda, click here. Registration is free.

The conference will explore some of the ways health tech and biopharma intersect, from a conversation about digital medicines to virtual clinical trials.

The round table, the state of AI in drug discovery, will kick off the conference. Here is a description:

Artificial intelligence in healthcare is finally emerging from being overhyped to show practical applications. If he succeeds in the field of drug discovery, it will be a monumental achievement that will help to both accelerate and reduce the cost of drug development. Learn from experts where we stand in effectively using AI for drug discovery.

Moderator: Frank Vinluan, Senior Biopharmaceutical Reporter, MedCity News

Speakers:

• Chris Gibson, Co-Founder and CEO, Recursion
• Richard Law, Commercial Director, Exscientia
• Sana Mujahid, Principal Scientist, Aria Pharmaceuticals
• Eric Steager, Venture Capital Partner, Touchdown Ventures

There will also be a startup pitch competition. It will highlight companies developing technologies to address innovative approaches to clinical trial design, patient recruitment, remote patient monitoring, and more, all of which could transform clinical trials.

Among the Pitch Perfect judges are:

• Cris De Luca, Partner, Digital, Sanofi Ventures
• Jessica Federer, Partner, Boston Millennia Partners
• Joel Krikston, Managing Director of Venture Capital Investments and Head of Strategic Alliances for Innovation, Merck Global Health Innovation Fund
• Maxim Owen, Venture Capital Partner, Wavemaker Three-Sixty Health

Interested in sponsorship opportunities at this and other MedCity News conferences? Please contact MedCity News Editor Ken Montgomery at [email protected].